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ABSTRACT
Cytotoxic T cells (CTLs) play a key role in the control of
Hepatitis B virus (HBV) infection and viral clearance.
However, most of identiﬁed CTL epitopes are derived
from HBV of genotypes A and D, and few have been
deﬁned in virus of genotypes B and C which are more
prevalent in Asia. As HBV core protein (HBc) is the most
conservative and immunogenic component, in this
study we used an overlapping 9-mer peptide pool cov-
ering HBc to screen and identify speciﬁc CTL epitopes.
An unconventional HLA-A2-restricted epitope HBc141–
149 was discovered and structurally characterized by
crystallization analysis. The immunogenicity and anti-
HBV activity were further determined in HBV and HLA-
A2 transgenic mice. Finally, we show that mutations in
HBc141–149 epitope are associated with viral parame-
ters and disease progression in HBV infected patients.
Our data therefore provide insights into the structure
characteristics of this unconventional epitope binding to
MHC-I molecules, as well as epitope speciﬁc CTL
activity that orchestrate T cell response and immune
evasion in HBV infected patients.
KEYWORDS chronic hepatitis B, HLA-A2, HBc peptide,
CTL response, antiviral cytotoxity
INTRODUCTION
Around 350 million people worldwide are chronically infected
with Hepatitis B virus (HBV). Chronic HBV infection is a
major cause of cirrhosis, liver failure, and hepatocellular
carcinoma (HCC) (Lavanchy, 2005; Neuveut et al., 2010).
HBV-speciﬁc CD8+ T lymphocytes (CTL)-mediated immune
response is multi-speciﬁc, polyclonal, and vigorous during
acute hepatitis B (AHB), which plays a vital role in viral
control and viral clearance, as well as disease pathogenesis
(Yukihiro, 2012; Westover and Hughes, 2007; Tan et al.,
2008). Whereas HBV-speciﬁc CTL response is minimal or
undetectable in chronic hepatitis B (CHB) with viral persis-
tence and immune tolerance, indicating the key role of HBV-
speciﬁc T-cell response in determination of disease pro-
gression and outcome (Bertoletti and Gehring, 2006; Zhang
et al., 2013).
The HBV genome of ∼3.2 kb in length efﬁciently encodes
several overlapping viral proteins, including the polymerase,
core, HBe, envelope (Pre-S1, S2, S), and X proteins. Ana-
lysis of CTLs speciﬁc for viral epitopes within core (Sendi
et al., 2009; Liu et al., 2012;), envelope (Liu et al., 2008),
polymerase (Rehermann et al., 1995), and X (Hwang et al.,
2002) proteins showed that the highly conserved HBV core
protein (HBc) elicits the strongest CTL responses than other
viral proteins, suggesting that HBc-speciﬁc T cell response
may play a leading role in viral control and clearance. To
identify immune-dominant HBV-speciﬁc CTL epitopes,
especially epitopes from HBc protein, is therefore necessary
for monitoring T cell responses during disease progression,
as well as for developing epitope-based therapeutic vaccines
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against CHB (Inchauspe and Michel, 2007; Gordon et al.,
2013; Liu et al., 2013a, b).
So far 60 HBV-speciﬁc human leukocyte antigen (HLA)
class I restricted and 32 HBV-speciﬁc HLA class II restricted
epitopes have been identiﬁed in all 8 HBV genotypes
(Desmond et al., 2008; Liu et al., 2008; Guo et al., 2011;
Zhang et al., 2013; Chen et al., 2013; Tan et al., 2013).
However, most of these identiﬁed epitopes are derived from
HBV of genotypes A and D, few HLA class I restricted epi-
topes have been deﬁned in virus of genotypes B and C,
which are more prevalent in Asia. Meanwhile, currently the
mostly used methods to predict and identify T cell epitopes
are either by computer algorithms based on the mode of
peptide binding to MHC molecules, or measurement of T cell
responses of PBMCs simulated with panels of overlapping
peptides (Liu et al., 2011). These epitope identiﬁcation
strategies may ignore unconventional T cell epitopes as
computational analysis is largely based on the characteristic
of anchor residues.
In this study, an overlapping 9-mer peptide pool was used
to screen and identify HBV genotypes B- and C-derived T
cell epitopes. A new unconventional CD8+ T cell epitope
HBc141–149 derived from viral core protein, which shares
partial sequence identity with previously reported HBc141–
151 (Bertoni et al., 1997) and HBc139–148 (Lee et al., 1997),
was discovered. Its immunological function and clinical rel-
evance were further assessed.
RESULTS
Identiﬁcation of a new HLA-A*0201-restricted epitope
from HBV core protein
HBV core protein is the most conservative and immunogenic
component of HBV proteins. We used an overlapping 9-mer
peptide pool covering the whole length of core protein
(aa 1–150) and its variants (totally 191 peptides) for T2
binding assay to screen genotype B- and C virus-derived
HBcAg-speciﬁc Tcell epitopes (Zhang et al., 2013), as shown
in Fig. 1A. Several peptides were found to have high afﬁnity
for binding to HLA-A*0201 molecules, as evidenced by the FI
(0.72 for HBc183–191, 2.41 for HBc141–149, 2.64 for
HBc60–68 (V60), 2.47 for HBc18–27, and 0.04 for HBc82–90),
as shown in Fig. 1B. HBc141–149 spanning from HBc aa 141
to 149 was chosen as the focus of this study due to its high
binding afﬁnity among the top hits from screening. To deter-
mine the minimal sequence length of the epitope, panels of
N- or C-terminally truncated or extended peptides of
HBc141–149 were synthesized. The FIs of truncated peptide
HBc141–148 (STLPETTV) and HBc142–149 (TLPETTVV)
were only 0.124 and 0.151, respectively (Fig. 1C). The FIs of
decapeptides HBc140–149 (LSTLPETTVV) and HBc141–
150 (STLPETTVVR) were only 0.033 and 0.005, respectively
(Fig. 1D). All HBc141–149 truncated and extended peptides
displayed little binding to HLA-A*0201, which indicates that
the 9-mer peptide HBc141–149 is the optimized epitope in
length. In addition to T2 cell binding assay, the capability of
HBc141–149 to bind to HLA-A*0201 was observed in the
refolding assay (Fig. 1E).
The structure of HLA-A*0201/HBc141–149 complex
Next, the complex of HLA-A2 and HBc141–149 was pre-
pared for crystallization to characterize the binding features
of HBc141–149. The crystal structure of the HLA complex
was determined to 2.3 Å resolution (Table 1). The structure
of HLA-A*0201/HBc141–149 shows that HBc141–149 pos-
sesses a typical conformation of an HLA-A2-restricted 9-mer
epitope (Fig. 2A and 2B). The unambiguous electron den-
sities of HBc141–149 clearly show that position 2 (T2) and
position 9 (V9) are buried in pockets B and F, respectively
(Fig. 2C). Compared to the typical HLA-A2-restricted epi-
topes which have an anchor residue Leu or Met at position 2,
HBc141–149 has Thr at position 2. The side chain OH of Thr
does not disrupt its inserting into the hydrophobic pocket B
properly (Fig. 2D). Instead, the side chain OH of Thr can
form a strong hydrogen bond interaction with H atom of Glu
on the α1 domain of the heavy chain, which helps HBc141–
149 binding to the HLA-A2 heavy chain and stabilizes the
entire complex. The side chains of amino acids P4, E5, and
V8 protrude out from the HLA-A2 surface and may be
involved in Tcell receptor (TCR) attachment and recognition.
To the best of our knowledge, this is the ﬁrst structure
showing the binding features of HLA-A2 to HBc141–149 with
an unconventional P2 anchor Thr.
HBc141–149 peptide generates speciﬁc CTL response
in HLA-A2.1/Kb transgenic mice
Then, the immunogenicity of HBc141–149 epitope was
determined in vivo. Female HLA-A2.1/Kb transgenic mice
were immunized with HBc DNA-prime/HBc141–149 peptide
boost regimen three times, using heat shock protein gp96 as
adjuvant (Li et al., 2011). HBc141–149-speciﬁc CTL was
detected by ELISPOT assay 1 week after the last immuni-
zation. As can be seen in Fig. 3A, similar to the HBc18–27
peptide-immunized mice (positive control), a strong CTL
response was observed in splenocytes from HBc141–149
peptide-immunized mice (SFC, 145.4 ± 58.6). No peptide-
speciﬁc CD8+ T cell response was detected from HBc82–90
peptide-immunized mice (negative control). Similar results
were observed in the killing assay using HBV plasmid-
transfected 293T cells (Fig. 3B) or HBc141–149 peptide-
pulsed T2 cells (Fig. 3C) as target cells.
HBc141–149 is a naturally processed epitope in AHB
To further determine the epitope-speciﬁc CTLs, fresh PBMCs
from HLA-A2+ AHB patients were stimulated with HBc141–
149 peptide and detected by ex vivo IFN-γ ELISPOTassays.
As shown in Fig. 3D, a much higher peptide-speciﬁc CTL
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response was observed in PBMCs stimulated with HBc141–
149 or the immunodominant peptide HBc18–27 as the
positive control than negative control peptide HBc82–90
(119.68 ± 76.66 for HBc141–149 or 164.58 ± 112.41 for
HBc18–27 vs. 20.94 ± 17.57 for HBc82–90, both P < 0.01).
The high standard deviations observed in ELISPOT assay
may reﬂect the random between-patient variation. Taken
together, these results indicate that HBc141–149 is an HLA-
A2-restricted CD8+ Tcell epitope and is naturally processed in
patients with HBV infection.
HBc141–149 epitope elicits antiviral T cell immunity
in HLA-A2.1/HBV transgenic mice
Next, we examined whether HBc141–149 epitope was able to
induce anti-HBV T cell response using F1 hybrids of HBV
transgenic BALB/C mice and HLA-A2.1/kb transgenic mice as
the experimental model, which are HBV immunotolerant. HLA-
A2.1/HBV transgenic mice were immunized with an HBc DNA
prime/ HBc141–149 peptide boost formulation. As shown in
Fig. 4A, compared to mice immunized with negative control
peptide, the number of SFCs increased by around 6-fold in
HBc141–149 peptide-immunized mice. Similar result was
obtained in cytotoxicity assay using HBV plasmid-transfected
293T cells as target cells. We then evaluated HBc141–149
peptide-induced Tcell response could lead to inhibition of HBV.
Immunization with HBc141–149 led to a 35.5% decrease in
serum HBsAg levels (P < 0.05) (Fig. 4C), and a signiﬁcant
reduction of viral DNA levels (P < 0.05) (Fig. 4D) at week 8
compared to the negative control. Meanwhile, signiﬁcant lower
levels of serum HBsAg and viral DNA were observed after
immunization (at week 8) than those before immunization (at
week 0) inHBc141–149-treatedmice but not in control peptide-
treated mice. And these results indicate that the epitope-spe-
ciﬁc CTL response induced by the HBc141–149 could signiﬁ-
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Figure 1. Binding afﬁnity of HBc141–149 peptide to HLA-A*0201. (A) The overlapping method of 8 aa overlap was used to
synthesize a total of 191 nonapeptides covering HBc aa 1–150. (B) MHC stabilization assay with T2 cells was used to quantify
peptide binding afﬁnity of HBc18–27, HBc82–90, HBc183–191, HBc141–149, and HBc60–68 (V60) to HLA-A*0201 molecules by ﬂow
cytometry, respectively. HBc18–27 and HBc82–90 peptides served as positive and negative controls, respectively. The results shown
are representative of three independent experiments. (C and D) Measurement of the binding afﬁnity of HBc141–149N- or C-terminally
truncated (C) or extended (D) peptides to HLA-A*0201. HBc82-90 served as a negative control (NC). (E) In vitro refolding of HBC141–
149 peptide with HLA-A*0201 heavy chain and β2m. Gel ﬁltration chromatography was used to analyze the refolded complexes on a
Superdex200 16/60 column. The HLA complex with the expected molecular mass of 45 kDa eluted at the volume of 15.9 mL. The
HLA complex (peak 2) was analyzed by SDS-PAGE electrophoresis and coomassie blue staining (line 2).
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HBV accumulates mutations within HBc141–149
epitope in HBV-infected patients
Finally, to address the clinical relevance of the HBc141–149
epitope inCHB,mutationswithin this epitopewere analyzed in
197 CHB and 64 ACLF patients (Table 2). In CHB, compared
to patients infected with wild-type isolates (HBc141–149,
STLPETTVV), patients infected with HBc141–149 mutants
had much higher ALT levels (247.7 ± 18.62 vs. 545.2 ± 137.7,
P < 0.05) (Fig. 5A) and aspartate aminotransferase (AST)
levels (187.6 ± 13.78 vs. 1668 ± 700.5, P < 0.05) (Fig. 5B).
Notably, compared toCHBpatients infectedwithHBc141–149
wild-type viruses, patients with HBc141–149 mutants had
much higher (approximately 3.3-fold) HBV DNA loads
(P<0.05) (Fig. 5C). Therewerenostatistical differences in sex
and age between patients infected with the wild-type and
mutant isolates. The prevalence of the HBc141–149 muta-
tions increased with the disease progression in HBV-infected
patients (Fig. 5D). To investigate the impact of these sequence
variations within HBc141–149 epitope on its immunogenicity,
three 9-mer peptides containing main epitope variations of
HBcV149I, HBcT147A, and HBcT147C in CHB patients were
synthesized, respectively, for HLA-A2.1/Kb transgenic mice
immunization. As seen in Fig. 5E, compared to the wild-type
HBc141–149 peptide-immunized mice (SFC, 96.7 ± 6.02),
CTL responses by ELISPOT assay were signiﬁcantly
decreased in HBcV149I mutant peptide- (SFC, 66.3 ± 5.69) or
HBcT147Amutant peptide- immunizedmice (SFC, 73 ± 7.81).
Taken together, these results suggest that the HBc141–149
mutations associatedwith necroinﬂammation and higher HBV
levels, and it may also be associated with poor prognosis,
which may be due to viral immune evasion.
DISCUSSION
In this study, we identiﬁed a new HLA-A2-restricted CD8+ T
cell epitope HBc141–149 by screening an overlapping 9-mer
peptide pool covering HBV core protein. This unconventional
HLA-A2 restricted epitope was further determined and
structurally characterized by HLA-A2 transgenic mouse
model and crystallographic analysis. Moreover, we demon-
strated that the HBc141–149 epitope exhibits antiviral
capability in HLA-A2.1/HBV transgenic mice. Finally, our
results show that mutations in HBc141–149 epitope correlate
with clinically relevant parameters in CHB. Our work may
therefore provide a comprehensive evaluation of the impact
of the newly deﬁned epitope on viral speciﬁc T cell response
and suggests a possible immune evasion for maintenance of
viral persistence in patients with HBV infection.
The identiﬁcation of HBV-speciﬁc T cell epitopes is mostly
based on the binding mode of the peptides to MHC mole-
cules in silico prediction or assessing T cell responses with
panels of overlapping peptides in HBV-infected patients.
These methods are effective and rapid to purposefully
identify epitopes, however, a considerable number of atypi-
cal or unconventional epitopes may be ignored or missed by
these methods due to the limitation of anchor residues
analysis-based computation (Liu et al., 2011). In this study,
an overlapping 9-mer peptide pool was used to screen B and
C genotype-derived HBc-speciﬁc CTL epitopes, and
HBc141–149 was identiﬁed as a new 9-mer HLA-A2-
restricted T cell epitope. Importantly, similar numbers of
HBc141–149-speciﬁc and immunodominant epitope HBc18–
27-speciﬁc CD8+ T cells were observed in AHB patients
(Fig. 3C), indicating that HBc141–149 is an immunodomi-
nant epitope in HBV-infected patients. However, the newly
deﬁned epitope HBc141–149 (STLPETTVV) in this study
possesses Thr at position 2. Different T cell epitope predic-
tion programs, including SYFPEITHI (http://www.syfpeithi.
de/Scripts/MHCServer.dll/Epitope-Prediction.htm), NET-
MHC (http://www.cbs.dtu.dk/services/NetMHC/), and BIMAS
(http: //www-bimas.cit.nih.gov) show the binding score of the
epitope HBc141–149 to HLA-A2 is only 0, 1.465, and 0.414,
respectively. As HBc141–149 does not get a high score, it
could be omitted in conventional screening. Interestingly, as
for HBc141–149 (STLPETTVV), the side chain OH of Thr2
can form a stronger hydrogen bond interaction with Glu on
α1 domain of the heavy chain, which helps its inserting into












Resolution range (Å) 50.00–2.30
Total reﬂections 96418
Unique reﬂections 19518
Completeness (%) 99.8 (99.2)
Redundancy 4.9 (4.3)






Bond lengths (Å) 0.002
Bond angles (°) 0.627
Values in parentheses are given for the highest resolution shell.
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pocket B (Fig. 2D) of HLA-A*0201 and stabilize the entire
complex. Therefore, our data indicated that Thr may also act
as a dominant role as a P2 anchor for HLA-A2-binding
peptides, which may be taken into consideration in the future
designation of these online prediction programs.
CD8+ T cells are the main effector cells responsible for
viral clearance as well as disease pathogenesis during HBV
infection (Thimme et al., 2003; Harari et al., 2006; Ouyang
et al., 2013). As a consequence of long-term interaction
between HBV and infected patients, the virus evolves
mutations to reduce epitopes for evading immune detection
and clearance, especially escape from T cell recognition
(Maman et al., 2011; Westover and Hughes, 2007). Indeed,
nonsynonymous mutations in HBV epitope have been found
to be associated with disease progression in CHB (Kim
et al., 2011; Frelin et al., 2009). Consistent to these studies,
we found that mutations in the newly deﬁned epitope are
positively related to viral parameters and pathogenesis of
liver disease. The effect of mutations within HBc141–149 on
viral replication capability, as well as the potential impact of
the epitope-speciﬁc CTLs on the interplay of HBV and
chronically infected patients remains to be addressed.
In summary, this study indicates that HBc141–149 is an
immunodominant HLA-A2- restricted CTL epitope with
atypical binding characteristics to HLA-A2 molecules, has
potent anti-HBV immune activity and the clinical signiﬁcance
in patients with HBV infection. We further demonstrated that
mutations within this epitope may affect disease progression
in CHB. Given the key role of CD8+ T cells in viral clearance,
our work provides valuable insight for the functional impli-
cations of HBc141–149 epitope-speciﬁc T cell response in
HBV infection. Understanding the epitope-speciﬁc CTL
function in the complex regulation networks that orchestrate
T cell response, viral persistence and immunoevasion in
CHB will allow to predict disease progression and develop
immunotherapeutic approaches against HBV infection.
MATERIALS AND METHODS
Patients and blood samples
The database of HBV infected patients’ records built by the 302
Hospital (Beijing, China) (http://www.hbvdb.com) was used to per-
form the Clinical information analyses of HBc141–149. In this study
we investigated the associations between HBc141–149 and the
progress of liver disease or patients’ clinical indicators. The criteria
for diagnosis of acute hepatitis B (AHB), chronic hepatitis B (CHB),
acute on chronic liver failure (ACLF) complied with those of the
Management Scheme of Diagnostic and Therapy of Viral Hepatitis
and the Diagnostic and Treatment Guideline for Liver Failure, was
issued by the Chinese Society of Infectious Diseases and Parasi-
tology and the Chinese Society of Hepatology. CHB is further divided
into two groups: mild chronic hepatitis B (CHB-M) and severe
chronic hepatitis B (CHB-S). The criteria for CHB-M patients: mild-to-














Figure 2. Structure of HLA-A*0201 complexed with HBc141–149. (A) Overview of the structure of HBc141–149 peptide presented
by HLA-A*0201; HBc141–149 is presented in the peptide-binding cleft. (B) HBc141–149 peptide is presented in the peptide-binding
clefts with electron density at the 1σ contour level. (C) Residues Thr2 and Val9 (green sticks) are located in pocket B and pocket F of
HLA-A*0201. The heavy chain of HLA-A*0201 is show in gray surfaces. (D) The side chain OH of Thr forms hydrogen bond
interaction with H atom of Glu on the alpha 1 domain of the heavy chain.
An unconventional HBc epitope elicits CTLs RESEARCH ARTICLE









CHB-S. The criteria for CHB-S patients: severe liver disease with
evident clinical manifestation and signiﬁcant alteration of biochemi-
cal parameters (serum albumin level ≤32 g/L, serum total bilirubin
(TBIL) >85.5 μmol/L, plasma prothrombin activity (PTA) 40%–60%,
or serum cholinesterase <4500 IU/L (Xu et al., 2011). The criteria for
ACLF: a history of CHB with symptoms of extreme fatigue and
severe digestive problems with biochemical parameters of TBIL >10
times normal level (171 μmol/L) and PTA ≤40% (Yang et al., 2002).
All the enrolled patients’ clinical characteristics are described in
Table 2.
A total of 29 AHB patients were enrolled for blood collection,
which were divided into two groups: HLA-A2-positive (n = 19) and
HLA-A2-negative (n = 10). All patients were negative for HCV, HDV,
and HIV-1 infection. 10 mL of blood samples were collected from
each patient. All patients were hospitalized in Beijing 302 Hospital
from September 2010 to September 2011. All study participants
have written informed consent and the study was approved by the
Ethics Committee of Beijing 302 Hospital.
Mice
HBV transgenic BALB/c mice were purchased from Transgenic
Engineering Lab, Infectious Disease Center (Guangzhou, China),
which were generated with a viral DNA construct, pHBV1.3, con-
taining 1.3 copies of the HBV genome. Serum HBV s antigen
(HBsAg) and viral DNA, as well as HBc expression in hepatocytes in
mice’s liver, were tested positive for all transgenic mice. The HLA-



























































































































HLA-A2- (n = 10)
HLA-A2+ (n = 19)
A B
C D
Figure 3. Detection of HBc141–149 peptide-speciﬁc CD8+ T cell response in HLA-A2.1/Kb mice and AHB patients. Female
HLA-A2.1/Kb transgenic mice were immunized with an HBV DNA prime/peptide boost regimen at weeks 1, 3, and 4. HBc82–90 and
HBc18–27 peptides served as negative and positive controls in immunization, respectively. (A) Fresh splenocytes (5 × 105) isolated
from immunized mice were stimulated with HBc141–149, HBc18–27 or HBc82–90 peptide, and peptide-speciﬁc CTLs were detected
by IFN-γ ELISPOT assay. (B and C) 293T cells labeled with CFSE were transfected with pHBV1.3 as target cells (B), and T2 cells
labeled with CFSE were loaded with 20 μg/mL peptide at 37°C for 1 h as target cells (C). The target cells were then mixed with
HBc141–149-stimulated splenocytes at different ratios: 1:1, 1:10, and 1:20, or HBc18–27, HBc82–90-stimulated splenocytes served
as positive or negative controls. After 4 h, the mixed samples were stained with PI, and the killing of target cells were analyzed by
FACS. The data shown are the mean ± SD of ﬁve mice. (D) AHB patients (n = 29) were divided into HLA-A2-positive (n = 19) and
HLA-A2-negative (n = 10) groups. PBMCs (2 × 105/well) from these patients were stimulated with the indicated peptides for detection
of peptide-speciﬁc CTLs by ELISPOT assay. HBc82–90 peptide served as negative control for background evaluation in ELISPOT
assay. PBMCs from HLA-A2- patients were used for speciﬁcity evaluation of CTLs. Paired samples t-tests were used for ELISPOT
assay in AHB patients. *P < 0.05 and **P < 0.01 by t-test. Data are representative of two independent experiments.
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by Professor Huang WL (IMCAS, Beijing, China). The HLA-A2.1/Kb
mice and HBV transgenic mice were crossed to gain the F1 hybrids
of HLA-A2.1/HBV transgenic mice. All F1 hybrids were screened for
serum HBsAg by ELISA, viral DNA by real-time PCR, and HLA-A2
by PCR-SSP (PROTRANS, Deutschland) before experimental
manipulations.
Plasmid constructs
The wild-type HBc gene was cloned into pcDNA3.1 (Invitrogen) and
the recombinant plasmid was designated pcDNA3.1-HBc. pHBV1.3
containing 1.3 copies of the full-length HBV genomic sequence was
maintained in the lab.
Peptide synthesis
The HBc sequences of genotypes B and C were attained using the
protein database from NCBI and a total of 171 HBc sequences of
genotype B and 159 HBc sequences of genotype C included. The
sequences were compared and served as a basis on peptide
synthesis. If the variation rate of a certain amino acid (aa) was more
than 10%, a series of peptides associated with this variation would
be synthesized. We adopted the overlapping method (8-aa overlap)
to synthesize a total of 191 nonapeptides (9-mers) covering HBc1–
150 aa (Zhang et al., 2013). All of these peptides were synthesized
at Jier Biological (Shanghai, China), and their purity was determined
as >95%. The HBc18–27 (FLPSDFFPSV) and HBc82–90 (REL-
VVSYVN) peptides were used as positive and negative controls,
respectively.
Cell culture and transfection
The 293T cell line was obtained from the ATCC (Manassas, VA,
USA) and cultured in Roswell’s Park Memorial Institute medium
supplemented with 10% fetal bovine serum. The T2 cell line was
kindly provided by Professor BinGao (IMCAS, Beijing, China) and
cultured in RPMI 1640 with 10% fetal bovine serum (Gibco BRL,
Paisley, UK). The transfection reagent Lipo2000 (Invitrogen, USA)





































































































































Figure 4. Immunization with HBc141–149 peptide induces speciﬁc CTL responses inhibits viral replication in HLA-A2+/HBV
transgenic mice. F1 hybrids of HLA-A2.1/kb transgenic mice and HBV transgenic BALB/c mice (n = 5 in each group) were
immunized three times as in Fig. 3. (A) ELISPOT assay. Splenocytes from immunized mice were stimulated with HBc141–149
peptide, or with HBc82–90 or HBc18–27 as negative or positive controls. (B) 293T cells labeled with CFSE were transfected with
pHBV1.3 as target cells, and mixed with HBc141–149-stimulated splenocytes at different ratios: 1:1, 1:10, and 1:20, or with HBc18–
27 or HBc82–90-stimulated splenocytes served as positive or negative controls . After 4 h, the mixed samples were stained with PI
and analyzed by FACS. (C) Serum secretion of HBsAg was detected by ELISA every other week. (D) HBV DNA levels in serum were
quantiﬁed by real-time PCR at weeks 0 and 8. The data shown are the mean ± SD of ﬁve mice. Paired t-tests were used. *P < 0.05
and **P < 0.01. Data are representative of two independent experiments.
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Table 2. Clinical and virologic characteristic of CHB-M, CHB-S, and ACLF patients
CHB-M CHB-S ACLF P-Value
Numbers 95 102 64
Age (mean ± SD) 42.51 ± 13.7 43.37 ± 14.57 45.89 ± 12.09 P < 0.01
Gender (M/F) 12/83 18/84 13/42 P > 0.05
HBV genotype
B (%) 17 (17.9%) 17 (16.7%) 5 (7.8%) P > 0.05
C (%) 78 (82.1%) 85 (83.3%) 59 (92.2%) P < 0.01
HBc141–149 variation 3 (3.1%) 12 (11.8%) 9 (14.1%) P < 0.05
HBe positive (%) 72 (86.3%) 49 (47.1%) 6 (9.3%) P < 0.01
HBV DNA copies/Ml (mean) 2.53 × 106 8.26 × 106 1.31 × 106 P > 0.05
(range) (2354–3.5 × 107) (500–2.64 × 108) (5980–1.32 × 107)
ALT(IU/L) (mean ± SD) 140.2 ± 186.7 284.5 ± 283.6 211.8 ± 244.1 P < 0.01
AST(IU/L) (mean ± SD) 87.7 ± 91.0 322.3 ± 932.2 238 ± 257.9 P < 0.01
HBV, hepatitis B virus; CHB-M, mild chronic hepatitis B; CHB-S, severe chronic hepatitis B; ACLF, acute-on-chronic liver failure; M, male; F,























































































































































































Figure 5. The HBc141–149 mutations are correlated with ALT/AST levels, viral DNA loads and disease progression in HBV-
infected patients. (A–C) Distribution of serum ALT (A) and AST levels (B), and HBV DNA loads (C) in CHB patients infected with
HBV isolates containing wild-type (STLPETTVV) or mutant HBc141–149. Student’s t-test was used to determine P-values. *P < 0.05.
(D) Distribution of the HBc141–149 mutation rate in CHB and ACLF patients. CHB-M, mild chronic hepatitis B; CHB-S, severe chronic
hepatitis B; ACLF, acute-on-chronic liver failure. Pearson’s χ test was used to determine P-values. (E) Female HLA-A2.1/Kb
transgenic mice were immunized with the wild-type HBc141–149 or mutant (HBcV149I, HBcT147A or HBcT147C) peptide as in
Fig. 3. Fresh splenocytes (5 × 105) isolated from immunized mice were stimulated with wild-type or mutant peptide, respectively.
Peptide-speciﬁc CTLs were detected by IFN-γ ELISPOT assay.
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by the manufacturer. Cells and supernatants were harvested at 24 h,
48 h, and 72 h after transfection, respectively.
T2 binding assay
T2 cells were used to perform MHC stabilization assays as previ-
ously described (Zhou et al., 2006). The binding activity of each
peptide was calculated as the ﬂuorescent index (FI), and the FI was
determined by: (mean FITC ﬂuorescence with the given peptide −
mean FITC ﬂuorescence without peptide) (mean FITC ﬂuorescence
without peptide). Peptides regarded as epitopes with high afﬁnity
should meet the following criteria: FI ≥1.
Refolding, protein crystallography, and structure determination
Recombinant proteins of HLA-A*0201 heavy chain and β2m were
expressed in Escherichia coli (Garboczi et al., 1992.) and the gradual
dilution method was performed during refolding process (Liu et al.,
2012). Then, Superdex 200 10/300 GL gel ﬁltration chromatography
followed by Resource-Q anion-exchanged chromatography (GE
Healthcare) was used for the concentration and puriﬁcation of the sol-
uble portion of the refolded complex. The hanging-drop vapor diffusion
methodwas performed at 18°C to crystallize the puriﬁed complexes. At
a ﬁnal concentration of 10mg/mL in0.1mol/LBis-Tris (pH6.5) and25%
(w/v) polyethyleneglycol 3350,HLA-A0201/HBc141–149 crystalswere
obtained. Equippedwith anR-AXISV||++ image-plate detector, Rigaku
MicroMax007 rotating-anode X-ray generator was operated at 40 kV
and20mA(CuΚα;λ=1.5418Å) tocollect crystallographicdataat100K
in house. With Protein Data Bank (PDB) entry 1JF1 as the search
model, the structure of HLA-A*0201/HBc141–149 was determined by
molecular replacement with the program MolRep.
Immunization of mice
Mice (6–8 weeks old) were immunized i.m. with 50 μg of plasmid
pcDNA3.1-HBc or pcDNA3.1 (control) at week 1 and subcutane-
ously with 50 μg of HBc141–149 peptide bound to 30 μg of heat
shock protein gp96 as adjuvant (Li et al., 2011) at weeks 3 and 4,
respectively. Mice were sacriﬁced 1 week after the last immuniza-
tion. Splenocytes were isolated as previously described (Liu et al.,
2009). Each group contained ﬁve to seven mice.
IFN-γ ELISPOT assay
To detect epitope-speciﬁc T cells, enzyme-linked immunosorbent
spot (ELISPOT) assay was performed according to the manufac-
turer’s instruction. Brieﬂy, ninety-six well PVDF plates (BD-Pharmi-
gen, San Diego, CA) were precoated overnight at 4°C with the
coating Ab and blocked for 1 h at 37°C. Patient PBMCs (2 × 105) or
murine splenocytes (106) were added to each well together with
50 μg/mL of peptide and incubated at 37°C for 24–48 h with phy-
tohemagglutinin (PHA)-stimulated T cells as positive controls. Each
test was performed at least in triplicate. The spots were counted and
analyzed using an ELISPOT Reader (Cellular Technology Ltd, USA).
Cytotoxicity assay
293T cells were labeled with 2 μmol/L CFSE as target cells after
transfection with pHBV1.3 and seeded into a 96-well plate. Then
CTLs were added at different ratios: 1:1, 10:1, and 20:1. Plates
were incubated for 4–6 h at 37°C, and CFSE positive target cells
were stained with propidium iodide (PI) using a Vybrant Apoptosis
Assay Kit (Invitrogen, USA). In addition, T2 cells were loaded with
20 μg/mL HBc141–149 peptide at 37°C for 1 h as target cells,
and seeded into a 96-well plate. The cytotoxicity assay was
performed as described above. Each assay was performed in
triplicate.
Detection of HBsAg and HBeAg by ELISA, and HBV DNA by real-
time PCR
ELISAs and real-time PCR for detection of serum HBsAg, HBeAg
and viral DNA copies were performed as described (Fan et al.,
2013).
Statistical analysis
Differences between groups were determined using Student’s t-test.
Pearson’s χ test was used to detect the correlation between varia-
tion rate and disease progress in HBV infected patients. Clinical
statistical analyses were performed with SPSS version 16.0 soft-
ware (SPSS Inc., Chicago, Illinois). P values <0.05 were considered
signiﬁcant.
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